RNAC
Cartesian Therapeutics, Inc.Company Information
- Company Name
- Cartesian Therapeutics, Inc.
- CIK
- CIK0001453687
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- RNAC: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- RNAC
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-12-04
- Last sale
- 2026-01-06
- Shares purchased (TTM)
- 95,323
- Shares sold (TTM)
- 56,264
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 8,672,148
- Shares outstanding
- 29,467,130
- Ownership
- 29.43%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 9.59%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Available For Sale Securities Debt Securities Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 148 | 119 | 125 | 143 | 160 | 180 | 213 | 219 | 87 | 103 | 77 | 80 | ||||||
| Accounts Receivable Net Current | 0 | 0 | 1 | 1 | 0 | 2 | 1 | 5 | 32 | 2 | 6 | 5 | ||||||
| Contract With Customer Asset Net Current | - | - | - | - | - | - | 0 | 1 | 3 | 2 | 3 | 2 | ||||||
| Prepaid Expense And Other Assets Current | 6 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 2 | 3 | 5 | 3 | ||||||
| Assets Current | 154 | 122 | 129 | 147 | 163 | 185 | 217 | 229 | 125 | 111 | 91 | 90 | ||||||
| Property Plant And Equipment Net | 11 | 12 | 12 | 12 | 12 | 10 | 10 | 10 | 7 | 2 | 2 | 2 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Operating Lease Right Of Use Asset | 5 | 5 | 6 | 5 | 5 | 5 | 6 | 14 | 14 | 10 | 10 | 10 | ||||||
| Indefinite Lived Intangible Assets Excluding Goodwill | 94 | 94 | 94 | 151 | 151 | 151 | 151 | 151 | 151 | 151 | 151 | - | ||||||
| Goodwill | 48 | 48 | 48 | 48 | 48 | 48 | 48 | 48 | 48 | 48 | 48 | - | ||||||
| Restricted Cash And Cash Equivalents Noncurrent | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | ||||||
| Other Assets | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Equity Securities Without Readily Determinable Fair Value Amount | - | - | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Prepaid Expense And Other Assets Noncurrent | 5 | 6 | 6 | 6 | - | - | 1 | - | - | - | - | - | ||||||
| Assets | 319 | 288 | 296 | 373 | 389 | 409 | 435 | 455 | 348 | 325 | 305 | 106 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accrued Liabilities Current | - | - | - | - | - | - | - | - | - | - | - | 14 | ||||||
| Other Assets Noncurrent | - | - | - | - | 6 | 6 | 1 | - | - | - | 0 | - | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 2 | 1 | 2 | 0 | 2 | 0 | 1 | 3 | 3 | 3 | 0 | ||||||
| Loans Payable Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Accrued Liabilities And Other Liabilities | 15 | 10 | 9 | 8 | 8 | 9 | 12 | 9 | 11 | 10 | 16 | - | ||||||
| Operating Lease Liability Current | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 2 | 2 | 2 | ||||||
| Liabilities Current | 21 | 16 | 15 | 14 | 12 | 15 | 23 | 21 | 26 | 37 | 68 | 20 | ||||||
| Operating Lease Liability Noncurrent | 7 | 8 | 9 | 9 | 10 | 10 | 11 | 12 | 12 | 8 | 9 | 9 | ||||||
| Long Term Loans Payable | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Contract With Customer Liability Current | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 2 | 4 | ||||||
| Warrants And Rights Outstanding | - | - | - | 1 | - | - | - | - | - | - | - | 13 | ||||||
| Long Term Debt Noncurrent | 53 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Deferred Income Tax Liabilities Net | 7 | 7 | 7 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | - | ||||||
| Derivative Liabilities Current | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 28 | - | ||||||
| Liabilities | 444 | 437 | 423 | 409 | 391 | 431 | 442 | 455 | 449 | 442 | 445 | 46 | ||||||
Stockholders Equity | ||||||||||||||||||
| Contract With Customer Liability Noncurrent | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 4 | 4 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 725 | 718 | 701 | 699 | 696 | 693 | 690 | 687 | 561 | 559 | 179 | 502 | ||||||
| Retained Earnings Accumulated Deficit | -846 | -862 | -822 | -730 | -694 | -710 | -692 | -682 | -658 | -671 | -615 | -437 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | ||||||
| Stockholders Equity | -125 | -148 | -126 | -36 | -3 | -22 | -7 | 1 | -101 | -117 | -440 | 60 | ||||||
| Liabilities And Stockholders Equity | 319 | 288 | 296 | 373 | 389 | 409 | 435 | 455 | 348 | 325 | 305 | 106 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | 0 | - | - | - | 0 | 0 | 0 | 0 | 297 | - | ||||||
| Series A Preferred Stock | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | -0 | 1 | 0 | - | ||||||
| Series B Preferred Stock | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 10 | 9 | 9 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | ||||||
| Common Stock Shares Issued | 30 | 29 | 26 | 26 | 26 | 26 | 26 | 24 | 18 | 6 | 5 | 5 | ||||||
| Shares Outstanding | 30 | 29 | 26 | 26 | 26 | 26 | 26 | 24 | 18 | 6 | 5 | 5 | ||||||
| Temporary Equity Par Or Stated Value Per Share | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | ||||||
| Temporary Equity Shares Authorized | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 1 | - | ||||||
| Temporary Equity Shares Issued | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Temporary Equity Shares Outstanding | - | - | 0 | - | - | - | 0 | 0 | 0 | 0 | 0 | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCartesian Therapeutics, Inc. (RNAC) — SEC Financial Statements & Analysis
Cartesian Therapeutics, Inc. (RNAC) is a pharmaceutical preparations company, incorporated in DE. Cartesian Therapeutics, Inc. trades on Nasdaq as: RNAC. Cartesian Therapeutics, Inc. (RNAC)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Cartesian Therapeutics, Inc. carries a market cap of $307.05M, a P/E ratio of -2.03x, a P/B ratio of -2.45x, a P/S ratio of 141.04x, an enterprise value of $210.56M, and an EV/EBITDA multiple of -1.36x. On profitability, it posts a gross margin of 110.54%, an operating margin of -7136.38%, a net margin of -6950.48%, a Return on Equity (ROE) of 236.88%, and a Return on Assets (ROA) of -42.77%. Per share, it reports EPS of $-5.13, diluted EPS of $-5.07, free cash flow per share of $-2.67, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -1677.54% year-over-year, net income growth of 289.10% year-over-year, and EPS growth of 243.05% year-over-year. On the balance sheet, it maintains a current ratio of 7.48x, a quick ratio of 7.19x, working capital of $133.06M, a debt-to-equity ratio of -3.54x, a debt ratio of 1.39, an interest coverage ratio of -182.35x, free cash flow of $-78.61M (TTM), and net debt of $-96.49M. Figures sourced from SEC EDGAR.
- Market Cap
- $307.05M
- P/E TTM
- -2.03x
- EPS TTM
- $-5.13
- P/B TTM
- -2.45x
- ROE TTM
- 236.88%
- ROA TTM
- -42.77%
- Debt To Equity
- -3.54x
- Free Cash Flow TTM
- $-78.61M
- Net Revenue TTM Growth 1Y
- -1677.54%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Cartesian Therapeutics, Inc. in?
Cartesian Therapeutics, Inc. (RNAC) operates in the Pharmaceutical Preparations industry.
What exchange does RNAC trade on?
Cartesian Therapeutics, Inc. (RNAC) trades on the Nasdaq.
Where is Cartesian Therapeutics, Inc. incorporated?
Cartesian Therapeutics, Inc. is incorporated in DE.
When was Cartesian Therapeutics, Inc. (RNAC)'s most recent SEC filing?
Cartesian Therapeutics, Inc. (RNAC)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is RNAC's market cap?
Cartesian Therapeutics, Inc. (RNAC) has a market capitalization of $307.05M as of 2026-06-30.
What is RNAC's EPS (earnings per share)?
Cartesian Therapeutics, Inc. (RNAC)'s trailing twelve month EPS is $-5.13 as of 2026-06-30.
What is RNAC's ROE (return on equity)?
Cartesian Therapeutics, Inc. (RNAC)'s trailing twelve month Return on Equity (ROE) is 236.88% as of 2026-06-30.
What is RNAC's ROA (return on assets)?
Cartesian Therapeutics, Inc. (RNAC)'s trailing twelve month Return on Assets (ROA) is -42.77% as of 2026-06-30.
What is RNAC's EV/EBITDA?
Cartesian Therapeutics, Inc. (RNAC)'s trailing twelve month EV/EBITDA is -1.36x as of 2026-06-30.